Enavate's Zenas Pharma Footnote: Obexelimab Pipeline Watch
Inside ENAVATE's disclosed stake in Zenas BioPharma and why the Obexelimab pipeline is grabbing attention. Learn what...
This article explains the main drivers of stock index performance and how various factors influence broad market moves. It helps readers understand signals behind daily swings and long-term trends.
20,153 articlesInside ENAVATE's disclosed stake in Zenas BioPharma and why the Obexelimab pipeline is grabbing attention. Learn what...
When Nasdaq and S&P 500 slip together into correction territory, investors face questions and tough choices. This gui...
The Trade Desk faced a tougher path after missing Q1 revenue and guiding for a weaker Q2, triggering multiple downgra...
Astronics reports a mixed Q1 2026 that tests the durability of its backlog and margin recovery. This article breaks d...
Beazer Homes rebuffs Dream Finders' latest cash bid, arguing the price undervalues its assets and ongoing turnaround....
A practical guide to understanding finvolution (finv) 2026 earnings, what to watch in the Q1 transcript, and how to p...
As AI reshapes enterprise tech, investors wonder if CrowdStrike can translate vigilance into lasting outsized returns...
Broadcom posted a robust Q2 with AI-driven revenue rising sharply, but the stock pulled back. A bold market thesis, h...
A quiet, multi-layered shield sits between enterprises and danger. This article explains the invisible layer protecti...
Investors are resorting to a dividend-driven approach to cover a $1,500 monthly car payment without dipping into prin...
ASML Holdings rode a broad wave of positive signals in June, even without a fresh earnings release. This article brea...
Apple unveils a multiyear AI silicon plan, signaling a major shift toward in-house AI hardware. Our analysis maps a p...